000056824 001__ 56824
000056824 005__ 20200221144314.0
000056824 0247_ $$2doi$$a10.1371/journal.pone.0160313
000056824 0248_ $$2sideral$$a96285
000056824 037__ $$aART-2016-96285
000056824 041__ $$aeng
000056824 100__ $$aFernández, O.
000056824 245__ $$aLong-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis
000056824 260__ $$c2016
000056824 5060_ $$aAccess copy available to the general public$$fUnrestricted
000056824 5203_ $$aThe effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart® electronic device provides useful information about adherence to the treatment with subcutaneous (sc) interferon (IFN) ß-1a (Rebif®). The aim of the study was to determine long-term adherence to this treatment in patients with relapsing- remitting multiple sclerosis (RRMS). This retrospective multicentre observational study analysed 258 patients with RRMS who were receiving sc IFN ß-1a (Rebif®) treatment by using RebiSmart® until replacement (36 months maximum lifetime) or treatment discontinuation. Adherence was calculated with data (injection dosage, time, and date) automatically recorded by RebiSmart®. Patients in the study had a mean age of 41 years with a female proportion of 68%. Mean EDSS score at start of treatment was 1.8 (95% CI, 1.6-1.9). Overall adherence was 92.6%(95% CI, 90.6-94.5%). A total of 30.2% of patients achieved an adherence rate of 100%, 80.6% at least 90%, and only 13.2% of patients showed a suboptimal adherence (<80%). A total of 59.9% of subjects were relapse-free after treatment initiation. Among 106 subjects (41.1%) who experienced, on average, 1.4 relapses, the majority were mild (40.6%) or moderate (47.2%). Having experienced relapses from the beginning of the treatment was the only variable significantly related to achieving an adherence of at least 80% (OR = 3.06, 1.28-7.31). Results of this study indicate that sc IFN ß-1a administration facilitated by RebiSmart® could lead to high rates of adherence to a prescribed dose regimen over 36 months.
000056824 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000056824 590__ $$a2.806$$b2016
000056824 591__ $$aMULTIDISCIPLINARY SCIENCES$$b15 / 63 = 0.238$$c2016$$dQ1$$eT1
000056824 592__ $$a1.236$$b2016
000056824 593__ $$aAgricultural and Biological Sciences (miscellaneous)$$c2016$$dQ1
000056824 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000056824 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2016$$dQ1
000056824 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000056824 700__ $$aArroyo, R.
000056824 700__ $$aMartínez-Yélamos, S.
000056824 700__ $$aMarco, M.
000056824 700__ $$aMerino, J.A.G.
000056824 700__ $$aMuñoz, D.
000056824 700__ $$aMerino, E.
000056824 700__ $$aRoque, A.
000056824 700__ $$aMunoz, C.
000056824 700__ $$aForonda, J.
000056824 700__ $$aSanchis, G.
000056824 700__ $$aBarrero, F.
000056824 700__ $$0(orcid)0000-0002-9788-2083$$aAra, J.R.
000056824 700__ $$aOliva, P.
000056824 700__ $$aMenéndez, M.A.
000056824 700__ $$aSolar, D.M.
000056824 700__ $$aOterino, A.
000056824 700__ $$aBrieva, L.
000056824 700__ $$aEscartín, A.
000056824 700__ $$aRamió, L.
000056824 700__ $$aMartín, G.
000056824 700__ $$aBlanco, Y.
000056824 700__ $$aGarcía, R.
000056824 700__ $$aAyuso, T.
000056824 700__ $$aOlascoaga, J.
000056824 700__ $$aRodríguez-Antigüedad, A.
000056824 700__ $$aCoret, F.
000056824 700__ $$aBelenguer, A.
000056824 700__ $$aCervelló, Á.
000056824 700__ $$aPérez, N.
000056824 700__ $$aLópez, A.
000056824 700__ $$aCastro, M.D.
000056824 700__ $$aMeca, V.
000056824 700__ $$aBorrega, L.
000056824 700__ $$aPuerta, I.
000056824 773__ $$g11, 8 (2016), 0160313 [12p.]$$pPLoS One$$tPloS one$$x1932-6203
000056824 8564_ $$s1427059$$uhttps://zaguan.unizar.es/record/56824/files/texto_completo.pdf$$yVersión publicada
000056824 8564_ $$s101237$$uhttps://zaguan.unizar.es/record/56824/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000056824 909CO $$ooai:zaguan.unizar.es:56824$$particulos$$pdriver
000056824 951__ $$a2020-02-21-13:39:03
000056824 980__ $$aARTICLE